| 摘要: |
| ［摘要］ 目的 观察重复经颅磁刺激（rTMS）联合氢溴酸西酞普兰治疗脑卒中后睡眠障碍（PSSD）患者的临床疗效。方法 回顾性分析2021年4月至2023年1月于新乡医学院第一附属医院接受治疗的94例PSSD患者的临床资料。根据不同治疗方案将其分为对照组和联合组，每组47例。对照组予氢溴酸西酞普兰治疗，联合组予rTMS联合氢溴酸西酞普兰治疗，两组均连续治疗8周。比较两组总有效率，以及不同时间点睡眠质量、负性情绪、运动阈值（MT）和炎性因子水平。结果 联合组治疗后总有效率显著高于对照组（95.74% vs 78.72%； χ2=6.114，P=0.013）。经治疗后，两组匹兹堡睡眠质量指数（PSQI）、失眠严重程度指数量表（ISI）、贝克抑郁量表（BDI）、贝克焦虑量表（BAI）评分以及IL-6、TNF-α、IL-2水平呈下降趋势，MT呈上升趋势，差异有统计学意义（P<0.05）。治疗4周、8周后，联合组PSQI、ISI、BDI、BAI评分以及IL-6、TNF-α、IL-2水平低于对照组，MT高于对照组，差异有统计学意义（P<0.05）。结论 rTMS联合氢溴酸西酞普兰治疗PSSD患者疗效显著，可减轻炎症，提高MT，改善睡眠障碍及负性情绪。 |
| 关键词: 重复经颅磁刺激 氢溴酸西酞普兰 脑卒中后睡眠障碍 临床疗效 |
| DOI：10.3969/j.issn.1674-3806.2024.04.15 |
| 分类号:R 743.3 |
| 基金项目: |
|
| Observation on the clinical efficacy of repetitive transcranial magnetic stimulation combined with citalopram hydrobromide in treatment of post-stroke sleep disorder |
|
LI Jingyan, ZHANG Ping
|
|
Department of Neurology, the First Affiliated Hospital of Xinxiang Medical University, Henan 453000, China
|
| Abstract: |
| ［Abstract］ Objective To observe the clinical efficacy of repetitive transcranial magnetic stimulation(rTMS) combined with citalopram hydrobromide in treatment of post-stroke sleep disorder(PSSD). Methods The clinical data of 94 patients with PSSD who were treated in the First Affiliated Hospital of Xinxiang Medical University from April 2021 to January 2023 were retrospectively analyzed. The patients were divided into control group and combination group according to different treatment plans, with 47 cases in each group. The control group was treated with citalopram hydrobromide and the combination group was treated with rTMS combined with citalopram hydrobromide, and both groups were treated continuously for 8 weeks. The total effective rate, sleep quality at different time points, negative emotion, motor threshold(MT) and the levels of inflammatory factors were compared between the two groups. Results The total effective rate after treatment in the combination group was significantly higher than that in the control group(95.74% vs 78.72%; χ2=6.114, P=0.013). After treatment, the Pittsburgh Sleep Quality Index(PSQI), Insomnia Severity Index(ISI), Beck Depression Inventory(BDI), Beck Anxiety Inventory(BAI) scores, and the levels of interleukin(IL)-6, tumor necrosis factor-α(TNF-α) and IL-2 showed a downward trend while MT showed an increasing trend, and the differences were statistically significant(P<0.05). After 4 and 8 weeks of treatment, the PSQI, ISI, BDI and BAI scores as well as the levels of IL-6, TNF-α and IL-2 in the combination group were lower than those in the control group, and MT in the combination group was higher than that in the control group, and the differences were statistically significant(P<0.05). Conclusion The combination of rTMS and citalopram hydrobromide is significantly effective in the treatment of PSSD patients, which can reduce inflammation, increase MT, and improve sleep disorder and negative emotion. |
| Key words: Repetitive transcranial magnetic stimulation(rTMS) Citalopram hydrobromide Post-stroke sleep disorder(PSSD) Clinical efficacy |
